CompletedNCT00158990
Triiodothyronine with sertraline for unipolar or bipolar depression
About this title
Read the official source — NCT00158990Medication studyAges 18–70United States + IsraelBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Princeton and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 220
- Sponsor
- Hadassah Medical Organization
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Israel
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00158990
- Official title
Show the full official title
Triiodothyronine (T3) Supplementation in Bipolar and Unipolar Depression: A Random Assignment, Double Blind, Placebo-Controlled Study.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Princeton, United States · Jerusalem, Israel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Hadassah Medical Organization.
Did this study involve medication?
Yes. The study involved medication, including triiodothyronine and sertraline.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
